Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer
作者： Hua-Jun Chen , Tony S. Mok , Zhi-Hong Chen , Ai-Lin Guo , Xu-Chao Zhang
DOI: 10.1007/S12253-009-9167-8
关键词: Cancer research 、 Population 、 Progression-free survival 、 Gefitinib 、 Tyrosine-kinase inhibitor 、 T790M 、 Epidermal growth factor receptor 、 Lung cancer 、 Biology 、 Erlotinib Hydrochloride
摘要: To investigate the clinicopathologic and molecular features of T790M mutation c-MET amplification in a cohort Chinese non-small cell lung cancer (NSCLC) patients resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR TKI-resistant NSCLC (n = 29) corresponding tumor specimens, 53 samples postoperative TKI-naive were collected. exon 19, 20, 21 mutations analyzed. And gene copy number was determined. The 20 not detected population patients, but found 48.3% (14/29) enrolled patients. amplified 3.8% (2/53) highly 17.2% (5/29) cohort. Most frequently associated with non-smoker, adenocarcinoma activating mutations. Three male occurred wild-type EGFR, treatments following TKI resistance. Features indistinguishable from In group had median progression free survival (PFS) overall (OS) as 9.6 months 12.6 months, respectively; whereas PFS OS 4.1 8.0 respectively. These results suggest that can occur these genetic defects might be related different outcome. or -resistant share similarities features.
springer.com
sci-hub.se 参考文章(27)
Shinichi Toyooka, Katsuyuki Kiura, Tetsuya Mitsudomi, None, EGFR mutation and response of lung cancer to gefitinib. The New England Journal of Medicine. ,vol. 352, pp. 2136- ,(2005) , 10.1056/NEJM200505193522019
David Whitcombe, Jane Theaker, Simon P. Guy, Tom Brown, Steve Little, Detection of PCR products using self-probing amplicons and fluorescence. Nature Biotechnology. ,vol. 17, pp. 804- 807 ,(1999) , 10.1038/11751
Nack Cheon Bae, Myung Hwa Chae, Myung Hoon Lee, Kyung Mee Kim, Eung Bae Lee, Chang Ho Kim, Tae-In Park, Sung Beom Han, Sanghoon Jheon, Tae Hoon Jung, Jae Yong Park, EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients Cancer Genetics and Cytogenetics. ,vol. 173, pp. 107- 113 ,(2007) , 10.1016/J.CANCERGENCYTO.2006.10.007
A G Pallis, A Voutsina, Ar Kalikaki, J Souglakos, E Briasoulis, S Murray, A Koutsopoulos, M Tripaki, E Stathopoulos, D Mavroudis, V Georgoulias, ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer British Journal of Cancer. ,vol. 97, pp. 1560- 1566 ,(2007) , 10.1038/SJ.BJC.6604068
Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi, Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib Clinical Cancer Research. ,vol. 12, pp. 5764- 5769 ,(2006) , 10.1158/1078-0432.CCR-06-0714
Jin-Yuan Shih, Chien-Hung Gow, Pan-Chyr Yang, EGFR Mutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 353, pp. 207- 208 ,(2005) , 10.1056/NEJM200507143530217
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Cai-Cun Zhou, Wei Liu, Bin Jiang, Xin-Lin Mu, Jia-Ying Lin, Qing Zhou, Chong-Rui Xu, Zhen Wang, Guo-Chun Zhang, Tony Mok, Yi-Long Wu, Wen-Zhao Zhong, Long-Yun Li, Xiao-Tong Zhang, Li Zhang, Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China Journal of Thoracic Oncology. ,vol. 2, pp. 430- 439 ,(2007) , 10.1097/01.JTO.0000268677.87496.4C